IGD myeloma: Clinical, biological and laboratory features

Clinical Laboratory

Volumn 48, Issue 11-12, 2002, Pages 617-622

  Sinclair, David ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Bence Jones protein; IgD myeloma; Monoclonal free light chains; Multiple myeloma

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENCE JONES PROTEIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; METHYLPREDNISOLONE; PAMIDRONIC ACID; PARAPROTEIN; PREDNISOLONE; PROTEASOME INHIBITOR; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; VINCRISTINE;

AMYLOIDOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROPHORESIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LABORATORY PERSONNEL; LABORATORY TEST; MOLECULAR BIOLOGY; MYELOMA; PROTEIN ANALYSIS; PROTEINURIA; REVIEW; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY; TREATMENT PLANNING; WHOLE BODY RADIATION;

BENCE JONES PROTEIN; HUMANS; IMMUNOGLOBULIN D; MULTIPLE MYELOMA; PARAPROTEINS;

EID: 0036445062     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Macintyre, W. "Mollities and Fragilitas Ossium." MedicoChirurgical (London) 1850; 33:211-232.
2. Bence Jones, H. "Papers on Chemical Pathology, Lecture III" Lancet 1847; 2:88-92.
3. Clamp JR. Some aspects of the first recorded case of multiple myeloma. Lancet; 1967(2): 1354-1356
4. ; Williams and Wilkins, Baltimore, MD. 1999; pp: 2631-2680
5. Vladiutu AO. Immunoglobulin D: Properties, Management and Clinical Relevance. Clinical and Diagnostic Laboratory Immunology 2000; 7 (2): 131-140)
6. Preud'homme JL, Petit I, Barra A, Morel F, Lecron JC, Lelievre E. Structural and functional properties of membrane and secreted IgD. Mol Immunol 2000; 37 (15): 871-887
7. Blattner FR, Tucker PW. The molecular biology of Immunoglobulin D. Nature 1984; 307:417-422
8. Tamura H, Fujinaga T, Kuroume T. IgD antibody to Mycoplasma pneumoniae in human sera as measured by the RAST. Int Arch Allergy Appl Immunol 1982;69(4):335-9
9. Ritchie RF. IgD, antinuclear antibodies. Arthritis Rheum 1968; 11:506
10. Peng Z, Fisher R, Franklin Adkinson N. Total serum IgD is increased in atopic subjects. Allergy 1991; 46: 4336-444
11. van der Meer JW, Vossen JM, Radl J, van Nieuwkoop JA, Meyer CJ, Lobatto S et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984 May 19;1(8386): 1087-90
12. Rowe DS, Fahey JL. A new class of human immunoglobulin. I. A unique myeloma protein. J Exp. Med. 1965;121:171-178
13. Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999;13(6):1259-72
14. Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Euro J Haematology 1991;47(4):262-7
15. Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398-404.
16. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma: review of 153 cases. Arch Intern Med 1975;135:87-93
17. Le Quellec A, Bataille R, Levy-Robinet M, Santy J, Ciurana AJ. IgD multiple myeloma A retrospective study in the Languedoc region. Press Medicale 1989; 18: 1110-1113
18. Lin TL, Shih LY, Dunn P, Wang PN, Wu JH, Kao MC. Immunoglobulin D multiple myeloma. Changgeng Yi Xue Za Zhi 2000; 8: 451-457
19. Gleich GJ, Bieger RC, Stankiewic R. Antigen combining activity associated with Immunoglobulin D. Science 1969;165:606-607
20. Airoldi M, Pelucco I, Lamperti R, Gioia F. IgD myeloma: an aggressive variant. Description of a clinical case and review of the literature. Recenti Prog Med 1993;84(6):423427
21. Sinclair D, Cranfield T. IgD myeloma: a potential missed diagnosis. Ann Clin Biochem. 2001;38( 5):564-5.
22. Sinclair D, Ballantyne F, Shanley S, Caine E, O'Reilly D, Shenkin A. Estimation of paraproteins by immunoturbidimetry and electrophoresis followed by scanning densitometry. Ann Clin Biochem 1990; 27(4):335-7
23. Riches PG, Sheldon J, Smith AM, Hobbs JR. Investigation of the overestimation of immunoglobulins by immunochemical methods in the presence of monoclonal components. Ann Clin Biochem 1991;28:253-259
24. Kanoh T, Niwa Y. Nonsecretory IgD, (kappa) multiple myeloma. Report of a case and review of the literature. Am J Clin Pathol 1987; 88: 516-519
25. Arpin C, de Bouteiller O, Razanajaona D, Fugier-Vivier I, Briere F, Banchereau J et al. The normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene, Cmu-Cdelta switch, and lambda light chain expression. J Exp Med 1998;187(8):1169-78
26. Juge-Morineau N, Heirman C, Bakkus M, Van Camp B, Malfait R, Harousseau JL et al. Immunoglobulins D and M multiple myeloma variants are heavily mutated. Clin Cancer Res 1997; 3(12 Pt 1):2501-6
27. Hobbs JR Corbett AA. Younger age of presentation and extraosseus tumour in IgD, myelomatosis. Br Med J 1969;1:412-414
28. Shinamoto Y. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients. Cancer Detect Prev. 1995;19(5):426-35.
29. Bataille R, Harousseau JL. Multiple Myeloma. N Engl J Med 1997; 336:1657-1664
30. Momiyama N, Ishikawa T, Doi T, Ishiyama A, Kouno T, Takimoto A et al. Extramedullary Plasmacytoma of the Breast with Serum IgD Monoclonal Protein: A Case Report and Review of the Literature. Breast Cancer 1999; 6(3):217-221
31. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kakishita E. IgD, multiple myeloma preceding the development of extensive extramedullary disease without medullary involvement. Acta Haematol 2000;104(1):42-5
32. Watanabe Y, Endou A, Ooi S, Matsushima E, Shimisu Y, Nakashima K. Extraosseous epidural IgD myeloma presenting with compression myelopathy. Psychiatry Clin Neurosci 2000 Dec; 54(6):665-7
33. Mochizuki & Katayama Y, Kikuchi F, Saito I, Homori M. Immunoglobulin D myeloma presenting as an extraosseous soft tissue tumor. Skeletal Radiol 2001 Mar;30(3):166-9
34. Lolin YI, Lam CW, Lo WH, Au KL, Maserei JR. IgD, multiple myeloma with thoracic spine compression due to epidural extra-osseous tumour spread. J Clin Pathol. 1994 ;47(7):669-71
35. Uppal HS Harrison P. Extramedullary plasmacytoma of the larynx presenting with upper airway obstruction in a patient with long-standing IgD, myeloma. J Laryngol Otol. 2001;115(9):745-6.
36. Kawauchi K Ogasawara T Yasuyama M Ohkawa S Aiba M. Testicular involvement in IgD multiple myeloma. Rinsho Ketsueki. 2001;42(11):1128-33.
37. Nakajima T, Noguchi T, Kumahara Y, Sugihara A, Yamazaki T, Iwasaki T et al. Neuron specific enolase producing IgD multiple myeloma with high serum amylase activity. Rinsho Ketsueki 1995; 36(4): 359-364
38. Tomkova H, Ueda M, Arakawa & Arata J. Cheilitis granulomatosa associated with IgD myeloma. European Journal of Dermatology 1997; 7(1):59-61
39. Carninal I. Castellanos E, Mateos V, Astudillo A, Moreno C, Dieguez MA. Hyperammonaemic encephalopathy as the presenting feature of IgD multiple myeloma. I hitern Med 1993; 233(3):277-9
40. Patel K, Carrington PA, Bhatnagar S, Houghton JB, Routledge RC. IgD myeloma with multiple cutaneous plasmacytomas. Clin Lab Haematol. 1998;20(1):53-5.
41. Kyle RA. IgD multiple myeloma: a cure at 21 years. Am J Hematol 1988;29(1):41-3
42. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma, cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 843-854
43. Fibbe WE, Jansen J. Prognostic factors in IgD myeloma: a study of 21 cases. Scand J Haematol 1984; 33 (5): 471-475
44. O'Connor ML, Rice DT, Buss DH, Muss HB. immunoglobulin D benign monoclonal gammopathy- a case report. Cancer 1991;68:611- 616
45. Kinoshita T, Nagai K Murate T, Saito H, Fukatsu T, Hotta T. IgD monoclonal gammopathy of undetermined significance. Int J Haematol 1997; 65:169-172
46. Bladé J, Kyle RA. IgD monoclonal gammopathy with long term follow up. Br J Haematol 1994; 88: 395-396
47. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346(8):564-9
48. Tichy M, Mateja F, Urban P, Matuska M. IgD paraproteinernias. Neoplasma 1993;40(1):59-61
49. Vilpo JA, Irjala K, Viljanen MY, Klemi P, Kouvonen I, Ronne-maa T. delta-Heavy chain disease. A study of a case. Clin Immunol Immunopathol 1980;17(4):584-94
50. Rabbi H, Ghaffor M, Abbadi MC. Spontaneous enzymatic cleavage of IgD myeloma protein giving a pattern of delta heavy chain disease. Arch Inst Pasteur Alger 1989;57:135-40
51. Weber DM. Newly diagnosed multiple myeloma. Curr Treat Options Oncol 2002;3(3):235-45
52. The UK myeloma forum. British Journal of Haematology 2001;115;522-540
53. Kyle RA. Update of the treatment of multiple myeloma. The Oncologist 2001;6:119-2124
54. Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995;85(11):3077-85
55. Anderson KC 2000. Novel Biologically based therapies for myeloma. www.myelomia.org/myeloma/myeloma↗ws.jsp?type=detail&id=498
56. Stevenson, F.K. Anderson KC. Immunotherapy for Multiple Myeloma: Insights and Advances. Seminars in Hematology 1999;36:1-2.
57. Zweegman S, Huijgens PC. Treatment of myeloma: recent developments. Anticancer Drugs 2002 Apr;13(4):339-51
58. Cameron JS. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis and Transplantation 1999; 14 : 61-65
59. Takemori N, Kondo K, Kawamura T, Imai Y, Sakurai H, Sato T. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment. Am J Hematol. 2001;66(1):62-3
60. Fukuno K, Tsurumi H, Yamada T, Oyama M, Moriwaki H. Complete remission of plasmablastic IgD multiple myeloma induced by continuous infusion of low-dose cytarabine and etoposide. Rinsho Ketsueki 2000; 41(6):513-518
61. Ochiai N, Shimazaki C, Okano A, Hatsuse M, Takahashi R, Hirai H et al. Meningeal relapse after double peripheral blood stem cell transplantation in IgD meyeloma. Leuk Lymphoma 2002;43(3):641-643
62. Hiyoshi M, Hashimoto S, Ota T, Nakao T, Takubo T, Tagawa S, Tatsumi N. Long-term survival in a case of high-risk type IgD myeloma; a possibility of effectiveness of interferon-alpha and erythropoietin. Haematologia (Budap) 1997;28(3):177-80
63. Suzuki A, Iwase O, Ohkubo T, Nakano M, Toyama K. The successful use of natural alpha-interferon single therapy in multiple myeloma of IgD (lambda)-type Rinsho Ketsueki 1991;32(1):47-51